CI Investments Inc. Raises Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Posted by Defense World Staff on May 25th, 2023

CI Investments Inc. lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 87.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 739 shares of the biopharmaceutical company’s stock after buying an additional 345 shares during the period. CI Investments Inc.’s holdings in Alnylam Pharmaceuticals were worth $176,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Belpointe Asset Management LLC purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $25,000. Guardian Wealth Advisors LLC purchased a new position in Alnylam Pharmaceuticals in the third quarter valued at about $27,000. ANTIPODES PARTNERS Ltd purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $28,000. 1832 Asset Management L.P. purchased a new position in Alnylam Pharmaceuticals in the first quarter valued at about $88,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $95,000.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $185.92 on Thursday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $120.43 and a 12 month high of $242.97. The stock has a market cap of $23.15 billion, a P/E ratio of -21.39 and a beta of 0.48. The stock’s 50 day moving average price is $199.28 and its 200 day moving average price is $212.05.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.97) by $0.57. Alnylam Pharmaceuticals had a negative return on equity of 1,287.80% and a negative net margin of 93.13%. The firm had revenue of $319.29 million for the quarter, compared to analysts’ expectations of $312.53 million. During the same period last year, the firm earned ($2.00) EPS. The firm’s revenue was up 49.7% compared to the same quarter last year. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.45 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on ALNY. Needham & Company LLC reissued a “buy” rating and issued a $240.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, February 24th. Canaccord Genuity Group reduced their target price on Alnylam Pharmaceuticals from $310.00 to $291.00 and set a “buy” rating on the stock in a report on Friday, February 24th. Chardan Capital reaffirmed a “buy” rating and set a $250.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, February 24th. 92 Resources reaffirmed an “initiates” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 26th. Finally, Sanford C. Bernstein initiated coverage on Alnylam Pharmaceuticals in a report on Tuesday, March 21st. They set an “outperform” rating and a $243.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $247.20.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,839 shares of the stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $194.59, for a total transaction of $357,851.01. Following the completion of the transaction, the chief marketing officer now directly owns 6,800 shares of the company’s stock, valued at approximately $1,323,212. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,839 shares of the stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $194.59, for a total transaction of $357,851.01. Following the completion of the transaction, the chief marketing officer now directly owns 6,800 shares of the company’s stock, valued at approximately $1,323,212. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 7,615 shares of the stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $194.59, for a total value of $1,481,802.85. Following the transaction, the chief executive officer now directly owns 30,332 shares of the company’s stock, valued at $5,902,303.88. The disclosure for this sale can be found here. Insiders have sold a total of 35,871 shares of company stock worth $7,131,842 in the last three months. 1.40% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Profile

(Get Rating)

Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.